
More than 300 patients.
5 countries.
11 centers.
The test can be used to identify patients who can be at risk of rejection due to a lower response to immunosuppressants as measured with Immunobiogram -who might require an increase of immunosuppression dosage or a change in the immunosuppressive regimen prescribed-, and patients who can profit from a gradual reduction of immunosuppression to avoid severe side effects related with immunosuppression.